Evaluating Prognostic Factors in Node-Negative Breast Cancer
Author Information
Author(s): Eva J Kantelhardt, Martina Vetter, Marcus Schmidt, Corinne Veyret, Doris Augustin, Volker Hanf, Christoph Meisner, Daniela Paepke, Manfred Schmitt, Fred Sweep, Gunter von Minckwitz, Pierre-Marie Martin, Fritz Jaenicke, Christoph Thomssen, Nadia Harbeck
Primary Institution: Martin-Luther Universität, Halle Saale, Germany
Hypothesis
Can biological risk assessment using uPA/PAI-1 improve the identification of low-risk node-negative breast cancer patients compared to clinical-pathological assessment?
Conclusion
The NNBC 3-Europe trial demonstrated that biological testing can effectively classify node-negative breast cancer patients, potentially sparing many from unnecessary chemotherapy.
Supporting Evidence
- The trial included 4,149 patients from 153 centers in Germany and France.
- 60% of patients had standardized central quality assurance for uPA/PAI-1 measurement.
- 2,661 patients were classified as high-risk and received chemotherapy.
- No unexpected toxicities were observed in the treatment arms.
Takeaway
This study looked at how to tell which breast cancer patients really need chemotherapy. It found that some patients can skip it and still be okay.
Methodology
The trial compared biological risk assessment using uPA/PAI-1 with clinical-pathological assessment in node-negative breast cancer patients, randomizing high-risk patients to different chemotherapy regimens.
Potential Biases
Potential bias due to non-randomized selection of risk assessment methods by participating centers.
Limitations
The study's design did not allow for randomization of risk assessment methods, which may introduce bias.
Participant Demographics
Patients aged 18-65 with operable node-negative breast cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website